What are the diagnostic steps and treatment options for pulmonary mycetoma (aspergilloma)?

Pulmonary Mycetoma (Aspergilloma): Diagnosis and Treatment

Immediate Recommendation

For symptomatic single aspergilloma, particularly with hemoptysis, surgical resection is the definitive treatment of choice, preferably via video-assisted thoracic surgery (VATS). 1 Asymptomatic patients with stable disease can be safely observed with serial imaging every 3-6 months. 2

---

Diagnostic Approach

Clinical Presentation

The diagnosis requires a systematic evaluation combining clinical, radiological, and microbiological criteria present for at least 3 months:

Key symptoms to assess:

• Hemoptysis (present in ~65% of cases) - most common and potentially life-threatening 3
• Chronic cough
• Chest pain
• Shortness of breath
• Constitutional symptoms (weight loss, fatigue)

Underlying conditions to identify:

• Prior pulmonary tuberculosis (81% of cases) 3
• Bronchiectasis
• Sarcoidosis
• Bullous emphysema
• Previous lung abscess

Radiological Diagnosis

CT chest is the gold standard imaging modality 1:

• Look for a round/oval mass within a preexisting cavity
• Air crescent sign (meniscus sign): fungal ball separated from cavity wall by airspace
• Upper lobes are most commonly affected
• Prone positioning CT: demonstrates mobility of the fungal ball in 7/9 cases, confirming the diagnosis 3

Microbiological Confirmation

Aspergillus IgG antibody (precipitins) is the most sensitive test - elevated in >90% of patients 2:

• This is the primary confirmatory test
• Virtually all patients with aspergilloma have positive precipitins 4

Sputum studies (less reliable):

• Culture positive in >50% but neither sensitive nor specific 4
• PCR testing is more sensitive than culture 2

Biopsy (when needed):

• Direct microscopy or culture from tissue provides definitive diagnosis
• Reserved for unclear cases

---

Treatment Algorithm

For Single Aspergilloma

Asymptomatic patients with stable cavity size over 6-24 months:

• Observation with serial imaging every 3-6 months 2
• No antifungal therapy required

Symptomatic patients (especially with hemoptysis):

• Surgical resection is strongly recommended if no contraindications exist 1, 2
• VATS is preferred over open thoracotomy when technically feasible 1
• Lobectomy is the procedure of choice 5
• Post-operative mortality: 5.6% 3

Perioperative antifungal therapy:

• Not routinely required 2
• Consider voriconazole or echinocandin if moderate risk of surgical spillage exists (based on cavity location/morphology) to prevent Aspergillus empyema 2

For Chronic Cavitary Pulmonary Aspergillosis (CCPA) / Complex Aspergilloma

Asymptomatic patients without:

• Pulmonary symptoms
• Weight loss or significant fatigue
• Major pulmonary function impairment
• Progressive radiographic changes

→ Observe without antifungal therapy, follow every 3-6 months 2

Symptomatic patients OR those with:

• Progressive loss of lung function
• Radiographic progression
• Systemic symptoms

→ Minimum 6 months of oral antifungal therapy 2

First-line antifungal agents (strong recommendation):

• Itraconazole (preferred) 2
• Voriconazole (preferred) 2
• Effectiveness: 50-80% response rate 6

Second-line agent:

• Posaconazole for adverse events or clinical failure 2

Critical monitoring requirements:

• Azole serum concentrations (therapeutic drug monitoring mandatory) 1
• Drug interactions
• Hepatotoxicity and other adverse effects

For treatment failures or azole resistance:

• IV micafungin, caspofungin, or amphotericin B 2
• Note: Systemic amphotericin B monotherapy is ineffective for simple aspergilloma 6, 4
• Prolonged or lifelong therapy may be required 2

---

Management of Hemoptysis

Stepwise approach:

1. Oral tranexamic acid (first-line medical management) 2

2. Bronchial artery embolization (strong recommendation for significant bleeding) 2

3. Antifungal therapy to prevent recurrence 2

4. Surgical resection if above measures fail 2

Important caveat: Hemoptysis may indicate therapeutic failure and/or antifungal resistance - reassess treatment strategy 1

---

Surgical Considerations for CCPA

Surgery is an option for:

• Localized disease unresponsive to medical therapy
• Pan-azole-resistant Aspergillus fumigatus infection
• Persistent hemoptysis despite bronchial artery embolization 2

Critical warning: Outcomes are significantly less favorable than single aspergilloma surgery - careful risk assessment is mandatory before proceeding 2. Multicavity disease (complex aspergilloma) historically has poor surgical outcomes 1.

---

Key Clinical Pitfalls

1. Do not confuse pulmonary aspergilloma with subcutaneous mycetoma - the latter is a completely different entity caused by fungi or bacteria affecting skin/subcutaneous tissue 1, 7

2. Air crescent sign is not pathognomonic - differential includes hydatid cyst, Rasmussen aneurysm, pulmonary gangrene, intracavitary clot, lung cancer, and metastasis 8

3. Systemic amphotericin B alone is ineffective for aspergilloma and should not be used as monotherapy 6, 4

4. Surgery in poor candidates carries significant morbidity - post-operative complications occur in ~35% of cases 3

5. Progressive disease requires long-term commitment - some patients need lifelong antifungal therapy with continuous monitoring for toxicity and resistance 2